What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies.
about
Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).Relapse following successful electroconvulsive therapy for major depression: a meta-analysisUpdate on Neuromodulation for Treatment-Resistant DepressionA Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression.Biomarkers for depression: recent insights, current challenges and future prospects.Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)Treatment-resistant depression in primary care across CanadaMagnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disordersTachyphylaxis/tolerance to antidepressants in treatment of dysthymia: results of a retrospective naturalistic chart review study.Utilisation of search filters in systematic reviews of prognosis questions.Impaired prefronto-thalamic functional connectivity as a key feature of treatment-resistant depression: a combined MEG, PET and rTMS studySynergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.Predicting recurrence of depression.Advances in the Management of Treatment-Resistant DepressionDifferential co-expression and regulation analyses reveal different mechanisms underlying major depressive disorder and subsyndromal symptomatic depression.AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role.Blood Transcriptomic Markers in Patients with Late-Onset Major Depressive DisorderThe relationship between psychiatric morbidity and quality of life: interview study of Norwegian tsunami survivors 2 and 6 years post-disaster.Ketamine for depression: where do we go from here?Childhood neglect predicts the course of major depression in a tertiary care sample: a follow-up study.Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episodeThe ethics of research on deep brain stimulation for depression: decisional capacity and therapeutic misconception.Comparison between neurostimulation techniques repetitive transcranial magnetic stimulation vs electroconvulsive therapy for the treatment of resistant depression: patient preference and cost-effectiveness.GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketaminePeripheral biomarkers in animal models of major depressive disorder.Therapeutic armamentarium for treating depression.Therapeutic options in treatment-resistant depression.Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?The hidden third: improving outcome in treatment-resistant depression.Antidepressant drug development: Focus on triple monoamine reuptake inhibition.The contribution of proteomic studies in humans, animal models, and after antidepressant treatments to investigate the molecular neurobiology of major depression.Is treatment-resistant depression a useful concept?New use for an old drug: oral ketamine for treatment-resistant depression.Vagal Nerve Stimulation for Treatment-Resistant Depression.Are Concerns About Irremediableness, Vulnerability, or Competence Sufficient to Justify Excluding All Psychiatric Patients from Medical Aid in Dying?A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression.Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects.Blunted amygdala activity is associated with depression severity in treatment-resistant depression.Electroconvulsive therapy improves clinical manifestation with plasma BDNF levels unchanged in treatment-resistant depression patients.Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case.
P2860
Q24602982-1E897347-A4D1-44FB-A58D-E355957BA9EBQ24608138-9F737923-16A1-448F-AD6B-25988758820FQ26766211-1989654C-1E0D-4F71-8748-D702BD0E1281Q30383857-EBA24B62-D76C-4F13-8CF0-B6855A3BFD7DQ33704099-0F88CC6A-5A63-4BE4-A3A2-59BED6DD5A05Q33837167-AE58A4B8-6E5A-4189-844C-7E2C05C56598Q33861601-4F7E84D5-B41F-412B-9EF3-C9E64529DDB0Q34204211-CE2B9F00-5301-4893-8EFE-045893B4B77DQ34208946-6FDD5F5D-BCCE-49B3-9713-23DAD56F105FQ34486542-12E08162-1AAF-42A0-A668-DBFA9E20AF51Q34925015-3FAD88D7-600C-4911-90EA-950452899030Q35006487-7610E288-3CEB-4245-A092-2DF7F4E0E6A5Q35576918-BB37E7DF-E6DA-4704-B2AC-9B69EC33FE95Q35580600-02CC7516-B595-4385-A527-E528AA7EEF61Q35604108-45A843AC-C42C-45D8-8064-CDB22E54B750Q35753372-4B911ED3-5F80-4403-A9FC-F01627BD8E8CQ35939562-A2CB06E8-9356-4847-8667-6DBC6F2F96E5Q36035255-AFB9CD28-95CC-4B9F-A34C-C839FA20DBCCQ36223372-6213D576-F4A1-4FD0-B79D-BC65436DDC5EQ36325950-D3BA630E-D983-48DC-B3D0-517A108670B5Q36591265-CA0A27EC-0247-47A1-B857-97B16F28ADC1Q36761365-C5080C5A-3E90-4FA7-8EDB-C01301961471Q37158842-AA0804C0-8BDD-43D1-993E-0F13C2A5CF1BQ37172762-1FB2171C-2F59-46FD-8E99-074C01CC5980Q37176590-17B5E678-4FC8-4B0C-84DD-6C0F82EAC831Q37777008-AC97B65C-9C01-4732-B8A7-BD2F55F49054Q37881968-3A94BED1-FE33-450A-B24C-351DA542EFEFQ37958033-D2E09916-CBAE-4CA8-8174-733E5EDDEFAFQ37974998-BCC8A0EA-937D-4342-AD14-55DB8FBC89D6Q38260259-E12FF5C6-1F7D-4ED3-B4F8-8BD61BA57DB5Q38285544-3D6075C3-3D48-4D21-82DB-F92771558133Q38696595-E5E6BDB5-9927-4A67-AA48-76A9835E84E0Q38917733-5FA747A8-7A51-4B8C-AB9F-93DB042EEA31Q39353790-B8C5192A-C3F1-4784-8CE7-0AFA98843CAFQ39380527-A0129437-EB7F-4224-A227-5447396C55F6Q41439528-6F5E8EA2-DDBB-4869-BD5B-DA72CD23E939Q42694571-DE0954DF-8899-4042-B952-5784666FE9A1Q46315296-A18B6A0D-32C3-46AA-8574-4CDC860B97FFQ47947818-E4FDF295-A550-41E3-B1BF-413B8E5B5112Q48074026-50AC921E-CC86-4DF5-A991-65236389211A
P2860
What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
What happens to patients with ...... to long term outcome studies.
@ast
What happens to patients with ...... to long term outcome studies.
@en
What happens to patients with ...... to long term outcome studies.
@nl
type
label
What happens to patients with ...... to long term outcome studies.
@ast
What happens to patients with ...... to long term outcome studies.
@en
What happens to patients with ...... to long term outcome studies.
@nl
prefLabel
What happens to patients with ...... to long term outcome studies.
@ast
What happens to patients with ...... to long term outcome studies.
@en
What happens to patients with ...... to long term outcome studies.
@nl
P2093
P1476
What happens to patients with ...... to long term outcome studies.
@en
P2093
Andrew Papadopoulos
Anthony J Cleare
Catherine Donaldson
Kalypso Markopoulo
Sarah C Wooderson
P356
10.1016/J.JAD.2008.10.014
P577
2008-11-12T00:00:00Z